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Introduction 
Minimally invasive surgery and the ERAS (En-
hanced Recovery after Surgery) protocol revolution-
ized perioperative care for gastrointestinal surgical 
procedures [1–4]. While the most extensive research 
involved colorectal diseases, ERAS was found to be 
beneficial in other branches of surgery [5, 6]. Its ap-
plication diminished postoperative morbidity and 
reduced hospital length of stay [6]. In 2014 the ERAS 
Society published its guidelines for perioperative 
care after gastrectomy [7]. Many versions of the 
ERAS protocol, however, are still being used in dif-
ferent surgical departments [6, 8]. Nevertheless, the 
main elements of the ERAS protocol remain common 
[6]. Many authors report that introduction of the 
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A b s t r a c t
Introduction: The ERAS (Enhanced Recovery after Surgery) protocol revolutionized perioperative care for gastrointes-
tinal surgical procedures. However, little is known about the association between adherence to the ERAS protocol in 
gastric cancer surgery and the oncological outcome. 
Aim: To explore the relation between adherence to the ERAS protocol and the oncological outcome in gastric cancer 
patients.
Material and methods: We performed a  retrospective analysis of a  prospectively collected database of patients 
treated for gastric cancer between 2013 and 2016. All patients were treated perioperatively with a 14-item ERAS 
protocol. Every patient underwent regular follow-up every 3 months for 3 years after surgery. 80% compliance to the 
ERAS protocol was the goal during perioperative care. Based on the level of compliance, patients were divided into 
group 1 and group 2 (compliance of ≥ 80% and < 80%, respectively).
Results: Compliance to the ERAS protocol was not a risk factor for diminished overall survival – probability of 3-year 
survival was 63% in group 1 and 56% in group 2 (p = 0.75). The proportional Cox model revealed that only stage 
III gastric cancer was a risk factor of poor prognosis in patients operated on for gastric cancer (HR = 7.89, 95% CI: 
2.96–20.89; p = 0.0001).
Conclusions: High adherence to the ERAS protocol did not improve overall survival in our 3-year observation. Only 
the stage of the disease, according to the AJCC classification, was identified as a risk factor for poor prognosis.
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ERAS protocol improves the short-term outcomes as 
well as compliance to its elements [9]. However, the 
ERAS protocol is not as commonly used in gastric 
surgery. Studies on long-term outcomes in this field 
are lacking, too [10]. The advances in surgical tech-
nique currently are marginal; therefore we should 
investigate meticulously other items contributing 
to final outcomes of gastric cancer surgery [11]. 
Recently, several papers revealed that compliance 
to the ERAS protocol may affect long-term survival 
in patients with cancer [12, 13], which is the most 
objective benchmark in assessment of oncological 
treatment. The reason for this association is still un-
der investigation. So far, no such influence has been 
investigated regarding gastric cancer surgery. 
Aim
To evaluate whether adherence to the ERAS pro-
tocol affects survival in patients undergoing gastric 
cancer surgery.
Material and methods
We performed a retrospective analysis of a pro-
spective collected database of patients treated for 
gastric cancer between 2013 and 2016. In 2012 lap-
aroscopic total gastrectomy became the method of 
choice in gastric cancer. Qualification for preopera-
tive chemotherapy was performed based on ESMO 
guidelines [14]. All patients were treated periopera-
tively with a 14-item ERAS protocol (Table I). 
Every patient underwent regular follow-up every 
3 months for 3 years after surgery. It included gener-
al check-up and computed tomography imaging for 
recurrence and distant metastasis evaluation.
Operative technique
All patients underwent D2 gastrectomy with 
spleen preservation in the laparoscopic approach. 
Reconstruction of the digestive tract was done 
with the Roux-en-Y approach. The esophago-jejunal 
anastomosis was carried out with a  linear 45  mm 
GIA stapler and jejuno-jejunal anastomosis. In both 
anastomoses the common orifice was closed by 
a hand-sewn suture. No routine drainage of the peri-
toneal cavity was used. 
Inclusion criteria
Inclusion criteria were: 18 years old, histologi-
cally confirmed gastric adenocarcinoma, procedure 
performed with a laparoscopic approach (gastrecto-
my with D2 lymphadenectomy), and follow-up of at 
least 12 months. Patients with stage IV cancer ac-
cording to the AJCC classification, patients operated 
initially with an open approach and patients after 
conversion, patients who died within 30 days after 
the initial procedure, and patients requiring multivis-
ceral resections and patients with locally inoperable 
cancer were all excluded from the analysis. 
Outcome measures
For the study purposes, patients were divided 
into two groups depending on their compliance to 
the ERAS protocol. Patients with compliance of equal 
to or more than 80% formed group 1. Patients with 
compliance of less than 80% represented group 2. We 
did not include postoperative elements of the ERAS 
protocol in the adherence calculation. As a  result, 
compliance to the ERAS protocol was calculated by 
dividing the number of components fulfilled by 11.
Table I. ERAS protocol used in our department
 1. Preoperative counseling and patient’s education
 2.  Pre-operative carbohydrate loading (400 ml of Nutricia 
preOp 2 h prior to surgery)
 3.  Antithrombotic prophylaxis (Clexane 40 mg s.c. starting 
in the evening prior to surgery)
 4.  Antibiotic prophylaxis (preoperative ceftriaxone 2 g i.v. 
30–60 min prior surgery)
 5. Laparoscopic surgery
 6.  Balanced intravenous fluid therapy (< 2500 ml of intra-
venous fluids during the day of surgery, less than  
150 mmol sodium)
 7.  No nasogastric tubes postoperatively
 8. No drains left routinely
 9.  TAP block and standard anesthesia protocol
10.  Avoiding opioids, multimodal analgesia (oral when 
possible – paracetamol 4 × 1 g, ibuprofen 2 × 200 mg, 
metamizole 2 × 500 mg, or ketoprofen 2 × 100 mg)
11.  Postoperative oxygenation therapy (4–6 l/min)
12.  Early oral feeding (oral nutritional supplement 4 h post-
operatively – Nutricia Nutridrink or Nestlé Impact, light 
hospital diet and oral nutritional supplements on the 
first postoperative day, full hospital diet on the second 
postoperative day)
13.  Urinary catheter removal on the first postoperative day
14.  Full mobilization on the first postoperative day (getting 
out of bed, going to toilette, walking along the corridor, 
at least 4 h out of bed)
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The primary outcome was 3-year overall survival. 
The secondary outcomes were perioperative compli-
cations, length of stay, and recovery parameters.
Ethical approval
The study was approved by the local Ethics Review 
Committee (approval number 1072.6120.225.2017). 
All procedures were performed in accordance with 
the ethical standards laid down in the 1964 Declara-
tion of Helsinki and its later amendments. 
Statistical analysis
All data were analyzed with StatSoft Statistica 
v.13 (StatSoft Inc., Tulsa, OK, USA). The results are 
presented as mean ± standard deviation (SD), me-
dian and interquartile range (IQR), and hazard ratio 
(HR) with 95% confidence intervals (CI) when ap-
propriate. The study of categorical variables used 
the c2 test of independence. The Shapiro-Wilk test 
was used to check for normal distribution of data 
and Student’s test was used for normally distribut-
ed quantitative data. For non-normally distributed 
quantitative variables, the Mann-Whitney U  test 
was used. For the purposes of further analysis, the 
entire group of patients was divided into subgroups 
depending on compliance with the ERAS protocol 
(< 80% and ≥ 80%). This was the target compliance 
with the ERAS protocol in our department. Survival 
data were analyzed according to the Kaplan-Meier 
method. The log-rank test was used to detect dif-
ferences between groups. Univariate and multivar-
iate analysis was performed using Cox proportional 
hazards. The variables with p < 0.05 were included 
in the model. Results were considered statistically 
significant when the p-value was found to be less 
than 0.05.
Results
During the study period, 97 patients with gas-
tric cancer underwent total gastrectomy. Eventually, 
78 patients were included in the analysis (51 males 
and 27 females). Mean age was 61.2 ±10.7 years. 
Mean compliance to the ERAS protocol in the whole 
group was 75.6%.
Group 1 (patients with compliance > 80%) in-
cluded 34 patients and group 2 (patients with com-
pliance < 80%) included 44 patients. The groups 
did not differ in terms of sex, age, BMI, ASA class 
and comorbidities. Both groups were also similar in 
terms of stage of the disease. Forty-six (58%) pa-
tients required adjuvant chemotherapy; the number 
of individuals was not statistically different between 
groups. The data are summarized in Table II.
A subgroup analysis demonstrated that the pa-
tients in group 1 and group 2 did not statistically 
differ in terms of 3-year overall survival (Figure 1).
Patients in group 1 required shorter length of 
stay in the hospital (mean: 6.0 ±4.1 days vs. 10.4 
±13.3 days; p = 0.0052). However, multivariate re-
gression analysis revealed that only complications 
were a risk factor for prolonged hospitalization (β = 
–0.68; 95% CI: (–0.95, –0.42); p < 0.001). Patients 
with high compliance had a lower complication rate 
(20.6% vs. 29.5%), although the result did not reach 
statistical significance.
Univariate analysis of overall survival identified 
only stage III AJCC as a risk factor of poor prognosis 
in patients operated on due to gastric cancer (HR = 
7.89, 95% CI: 2.96–20.89; p = 0.0001; Table III).
According to Kaplan-Maier curves, probability of 
3-year overall survival for group 1 was 63% and 56% 
(12/44) for group 2 (Figure 2). These two groups did 
not differ statistically significantly (p = 0.75).
Kaplan-Maier curves show decreased probabili-
ty of overall survival in patients with stage III AJCC, 
which is 28 in 3-year observation (Figure 3). In pa-
tients with stage I and II overall survival was 87% 
(p < 0.001).
We also analyzed the influence of complications 
on overall survival. There were no statistically sig-
nificant differences between groups of patients with 
no complications, patients with Clavien-Dindo I–II 
complications and patients with Clavien-Dindo III–IV 
complications (p = 0.22).
Discussion
Our study showed that compliance to the ERAS 
protocol positively impacts short-term outcomes, 
but it does not influence 3-year survival. The only 
factor that worsens the patient’s prognosis is the 
stage of the disease. This is to our best knowledge 
the first study investigating this problem.
Compliance to ERAS seems not to influence pa-
tient survival. Our findings are contrary to Gustafs-
son et al., who observed improved long-term out-
comes in colorectal cancer surgery in patients with 
high compliance to the ERAS protocol [12]. Pisarska 
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Table II. Demographic analysis of patient group
Parameter Total Group 1 Group 2 P-value
Number of patients, n 78 34 44 –
Females, n (%) 27 (34.6) 10 (29.4) 17 (38.6) 0.3939
Males, n (%) 51 (65.4) 24 (70.6) 27 (61.4)
Age, mean ± SD [years] 61.2 ±10.7 61.1 ±10.3 61.3 ±11.2 0.9466
BMI, mean ± SD [kg/m2] 25.7 ±4.1 25.5 ±3.7 25.9 ±4.4 0.7772
ASA 1, n (%) 1 (1.3) 1 (2.9) – 0.5581
ASA 2, n (%) 62 (79.5) 27 (79.4) 35 (79.5)
ASA 3, n (%) 14 (17.9) 6 (17.6) 8 (18.2)
ASA 4, n (%) 1 (1.3) – 1 (2.3)
Any comorbidity, n (%) 53 (67.9) 26 (76.5) 27 (61.4) 0.1525
Cardiovascular, n (%) 19 (24.4) 8 (23.5) 11 (25) 0.8806
Hypertension, n (%) 28 (35.9) 11 (32.4) 17 (38.6) 0.5654
Diabetes, n (%) 9 (11.5) 2 (5.9) 7 (15.9) 0.1553
Liver disease, n (%) 5 (6.4) 1 (2.9) 1 (2.3) 0.8536
Operative time, median (IQR) [min] 307.4 ±90.9 275 (242–332) 300 (240–355) 0.6511
Intraoperative blood loss, median (IQR) [ml] 317 ±272.6 200 (200–300) 200 (150–500) 0.4491
Conversion, n (%) 3 (3.8) 1 (2.9) 2 (4.5) 0.7149
Neoadjuvant treatment, n (%) 53 (67.9) 24 (70.6) 29 (65.9) 0.6599
Adjuvant treatment, n (%) 46 (59) 19 (56) 27 (61) 0.8037
AJCC Stage 0, n (%) 5 (6.4) 2 (5.9) 3 (6.8) 0.7004
AJCC Stage I, n (%) 22 (28.2) 11 (32.4) 9 (20.5)
AJCC Stage II, n (%) 20 (25.6) 7 (20.6) 11 (25)
AJCC Stage III, n (%) 31 (39.7) 14 (41.2) 21 (47.7)
Tumor grade G1, n (%) 1 (1.3) – 1 (2.3) 0.5329
Tumor grade G2, n (%) 46 (59.0) 21 (61.8) 25 (56.8)
Tumor grade G3, n (%) 31 (39.7) 13 (38.2) 18 (40.9)
Time to first flatus, mean ± SD [days] 2.6 ±1.2 2.6 ±0.9 2.6 ±1.4 0.9874
Patients without complications, n (%) 58 (74.4) 27 (79.4) 31 (70.7) 0.3656
Patients with complications, n (%) 20 (25.6) 7 (20.6) 13 (29.5)
Clavien-Dindo 1, n (%) 3 2 (5.9) 1 (.2.3) 0.4358
Clavien-Dindo 2, n (%) 6 (7.7) 1 (2.9) 5 (11.4)
Clavien-Dindo 3, n (%) 7 (9.0) 2 (5.9) 5 (11.4)
Clavien-Dindo 4, n (%) 3 (3.8) 1 (2.9) 2 (4.5)
Length of hospital stay, mean ± SD [days] 8.3 ±10.1 6.0 ±4.1 10.4 ±13.3 0.0052
Length of hospital stay, median (IQR) [days] 6 (4–8) 5 (4–6) 7 (5–8)
Readmission, n (%) 11 (14.1) 6 (17.6) 5 (11.4) 0.4319
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et al. also found benefit of adherence to the ERAS 
protocol, observing better overall survival in patients 
with at least 80% compliance [13]. However, it is not 
easy to explain the why ERAS could possibly improve 
oncological outcomes. Asklid et al. reported that bal-
anced fluid therapy in the perioperative course also 
could improve 5-year survival [15]. The topic is still 
under investigation, and it is highly likely that better 
survival is a consequence of many marginal gains in 
the perioperative period.
The ERAS protocol improves short-term out-
comes, diminishing the rate of postoperative com-
plications [16–18]. Some authors suggest that 
complications may negatively impact long-term sur-
vival [19]. Wang et al. performed a meta-analysis in 
which they found that postoperative complications 
correlate with poor survival in patients with stage 
II and III of the disease [20]. However, in patients 
with stage I complications it had no impact on the 
Figure 1. Patients flow through the study
Assessed for eligibility (n = 97)
Laparoscopic procedure (n = 92)
Included patients (n = 78)
Excluded: open surgery (n = 5)
Excluded (n = 14)
•	 Stage IV in AJCC classifica- 
tion (n = 4)
•	 30-day mortality (n = 3)
•	 Multivisceral resection (n = 1)
•	 Lost to follow-up (n = 6)
Table III. Univariate analysis of overall survival
Parameter HR (95% CI) P-value
Sex (female vs. male) 1.13 (0.52–2.48) 0.7534
Age (< 65 vs. ≥ 65 years) 1.01 (0.47–2.16) 0.9781
BMI (< 25 vs. ≥ 25 kg/m2) 0.49 (0.22–1.07) 0.0729







Hypertension (no vs. yes) 0.88 (0.40–1.97) 0.7659
Diabetes (no vs. yes) 0.77 (0.18–3.28) 0.7283
Liver disease (no vs. yes) 1.02 (0.58–1.28) 0.4334
Renal disease (no vs. yes) 1.27 (0.46–1.72) 0.7318
Adherence to ERAS  
(< 80%)
0.83 (0.37–1.85) 0.6620
AJCC (I–II vs. III) 7.87 (2.96–20.89) < 0.0001
Adjuvant chemotherapy 2.5 (0.51–12,32) 0.2500
Duration of the surgery 
(< 300 vs. > 300 min)
0.81 (0.38–1.71) 0.5715
Intraoperative blood loss 
(< 200 vs. > 200 ml)
1.58 (0.21–2.02) 0.6113
Postoperative complica-
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Figure 2. Kaplan-Meier survival estimates accord-
ing to ERAS protocol adherence
 0 10 20 30 40 50 60
Time [months]
 AJCC I–II          AJCC III
Figure 3. Kaplan-Meier survival estimates accord-
ing to stage of the disease
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oncological outcomes [20]. On the other hand, Cli-
ment reported the following risk factors for worse 
survival: male gender, stage III of the disease and D1 
lymphadenectomy; complications however were not 
associated with worse long-term prognosis [21]. In 
our study, only stage III cancer was a risk factor for 
poor survival. However, we did not assess the type 
of lymphadenectomy, because D2 lymphadenecto-
my in our unit is performed routinely.
Patients with high compliance had a  significant 
shorter length of stay in comparison to those with 
low compliance. This result are in line with many oth-
er studies, as shortening of LOS is one of the main 
benefits of the ERAS protocol reported in the litera-
ture. Li et al. in their meta-analysis of 6 randomized 
control trials confirmed the benefit also for patients 
undergoing gastrectomy for gastric cancer [22].
What is important is that the ERAS protocol has 
many different modifications. Implemented proto-
cols vary, including between 12 and 25 elements 
[23–25]. In our department we use a  14-element 
protocol for gastric cancer, and 16 elements for col-
orectal procedures [13, 26]. However, most of the el-
ements are common for all ERAS protocols.
In our study we decided not to include postoper-
ative elements in ERAS adherence calculation. Also, 
in our high compliance group, we observed a signifi-
cantly shorter length of hospital stay. Moreover, we 
observed fewer Clavien-Dindo II–IV complications 
in the high compliance group, although the data 
did not reach statistical significance. On the other 
hand, Aarts et al. found that postoperative compo-
nents have the strongest impact on overall result 
[27]. Having said that, they still underline the signifi-
cance of preoperative elements. Kehlet also stresses 
that core elements of ERAS improve the final out-
comes [28]. We focused on pre- and intraoperative 
elements of ERAS, because they are mostly staff-de-
pendent. Moreover, these elements influence the 
compliance with postoperative elements, which in 
this situation could be regarded as an outcome. It 
is also worth remembering that not only periopera-
tive care but also proper surgical technique with D2 
lymphadenectomy and neoadjuvant treatment are 
the basis of a good final outcome.
There are some limitations of our study. Firstly, 
our sample size is fairly small and some subgroups 
might be underpowered for adequate statistical 
analysis, especially in patients with Clavien-Dindo 
grade III and IV complications. Secondly, we also 
used the national personal identification number 
database to gather data on overall survival, which 
allows us to access only date of death but not infor-
mation whether the death was cancer-specific. Next, 
the impact of the learning curve of laparoscopic gas-
trectomy has to be taken into consideration due to 
the complexity of the procedure requiring a signifi-
cant number of cases for proficiency [29]. That could 
be a possible source of bias in the early stages of the 
study. Finally, we do not have complete information 
about adjuvant therapy, since some of our patients 
chose the treatment in other oncological centers.
Conclusions
High adherence (80% and higher) to the ERAS 
protocol does not improve overall survival in our 
3-year observation. Only the stage of the disease ac-
cording to the AJCC classification was identified as 
a risk factor for poor prognosis. 
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